Role of cannabinoids in the management of neuropathic pain

CNS Drugs

Volumn 22, Issue 8, 2008, Pages 645-653

  Martín Fontelles, M Isabel ^a   Goicoechea García, Carlos ^a  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

Ajulemic acid, therapeutic use; Cannabidiol, therapeutic use; Cannabinoids, therapeutic use; Dronabinol, therapeutic use; Marijuana, therapeutic use; Multiple sclerosis, management; Nabilone, therapeutic use; Neuropathic pain, management

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 5 (1,1 DIMETHYLHEPTYL) 2 (3 HYDROXY 7 HYDROXYMETHYLDECAHYDRO 1 NAPHTHYL)PHENOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; AJULEMIC ACID; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; DEXANABINOL; DRONABINOL; NABILONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PLACEBO; RIMONABANT;

ANTINOCICEPTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG EFFICACY; DYSPHAGIA; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPOTENSION; INFLAMMATION; LIMB WEAKNESS; MEMORY DISORDER; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; MYALGIA; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; XEROSTOMIA;

ANIMALS; CANNABINOIDS; CANNABIS; HUMANS; NEURALGIA; PAIN MEASUREMENT; RECEPTORS, CANNABINOID;

EID: 46749085464     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200822080-00003     Document Type: Review

References (85)

1. Mechoulam R. The pharmacohistory of cannabis sativa. In: Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton (FL): CRC Press, 1986: 1-20
2. Reynolds JR. Therapeutical uses and toxic effects of Cannabis indica [letter]. Lancet 1890; 22: 637
3. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 1646-7
4. Devane WA, Dysarz FA, Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-13
5. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4
6. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9
7. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 2005; 7 (3): E625-54
8. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990; 87: 1932-6
9. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-80
10. Pertwee RG. Pharmacological, physiological and clinical implications of the discovery of cannabinoid receptors. Biochem Soc Trans 1998; 26 (2): 267-72
11. Skaper SD, Buriani A, Dal Toso R, et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Nat Acad Sci U S A 1996; 93 (9): 3984-9
12. Sagan S, Venance L, Torrens Y, et al. Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes. Eur J Neurosci 1999; 11 (2): 691-9
13. Griffin G, Fernando SR, Ross RA, et al. Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol 1997; 339: 53-61
14. Calignano A, La Rana G, Giuffrida A, et al. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394 (6690): 277-81
15. Malan P, Ibrahim M, Deng H, et al. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 2001; 93: 239-45
16. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90
17. Pertwee R, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 101-21
18. Howlet AC, Barth F, Bonner T, et al. International Union of Pharmacology: XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202
19. Goya P, Jagerovic N, Hernández-Folgado L, et al. Cannabinoids and neuropathic pain. Mini Rev Med Chem 2003; 3 (7): 765-72
20. Hillard CJ, Jarrahian A. Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol 2003; 140: 802-8
21. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997; 388: 773-8
22. Hanus L, Abu Lafi S S, Fride E, et al. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 2001; 98: 3662-5
23. Porter AC, Sauer JM, Knierman MD, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002; 301: 1020-4
24. Huang SM, Bisogno T, Trevisani M, et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A 2002; 99: 8400-5
25. Pertwee R. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006; 147: S163-71
26. Di Marzo V, De Petrocellis L, Bisogno T. The biosynthesis, fate and pharmacological properties of endocannabinoids. In: Pertwee RG, editor. Cannabinoids: handbook of experimental pharmacology. Vol. 168. Heidelburg: Springer-Verlag, 2005: 147-85
27. Grotenhermen F. Cannbinoids. Curr Drug Targets CNS Neurol Disord 2005; 4 (5): 507-30
28. Buxbaum DM. Analgesic activity of delta-9-tetrahydrocannabinol in the rat and mouse. Psychopharmacologia 1972; 25: 275-80
29. Sofia RD, Vassar HB, Knobloch LC. Comparative analgesic activity of various naturally occurring cannabinoids in rats and mice. Psychopharmacologia 1975; 40: 285-95
30. Johnson MR, Melvin LS, Milne GM. Prototype cannabinoid analgetics, prostaglandins and opiate search for points of mechanistic interaction. Life Sci 1982; 31: 1703-6
31. Dajani EZ, Larsen KR, Taylor J, et al. 19,19-Dimethylheptyl-D-8- tetrahydrocannabinol-11-oic acid: a novel, orally effective cannabinoid with analgesic and anti-inflammatory properties. J Pharmacol Experiment Ther 1999; 291: 31-8
32. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63: 569-611
33. De Vry J, Denzer D, Reissmueller E, et al. 3-[2-cyano-3-(trifluoromethyl) phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects. J Pharmacol Exp Ther 2004; 310 (2): 620-32
34. Smith FL, Fujimori K, Lowe J, et al. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharm Biochem Behavior 1998; 60 (1): 183-91
35. Choong KC, Su X, Urban MO. Effect of CP55,940 on mechanosensory spinal neurons following chronic inflammation. Neurosci Lett 2007; 414 (2): 105-9
36. Vann RE, Cook CD, Martin BR, et al. Cannabimimetic properties of ajulemic acid. J Pharmacol Exp Ther 2007; 320 (2): 678-86
37. Beaulieu P, Bisogno T, Punwar S, et al. Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol 2000; 396 (2-3): 85-92
38. Guindon J, Desroches J, Beaulieu P. The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br J Pharmacol 2007; 150 (6): 693-701
39. Calignano A, La Rana G, Iufrida A, et al. Control of pain initiation by endogenous cannabinoids. Nature 1998; 396: 277-81
40. Amaya F, Shimosato G, Kawasaki Y, et al. Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonist. Pain 2006; 124 (1-2): 175-83
41. Romero-Sandoval A, Eisenach JC. Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision. Anesthesiology 2007; 106 (4): 787-94
42. Vann RE, Cook CD, Martin BR, et al. Cannabimimetic properties of ajulemic acid. J Pharmacol Exp Ther 2007; 320 (2): 678-86
43. La Rana G, Russo R, Campolongo P, et al. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. J Pharmacol Exp Ther 2006; 317 (3): 1365-71
44. Martin WJ, Loo CM, Basbaum AI. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain 1999; 82 (2): 199-205
45. Agarwal N, Pacher P, Tegeder I, et al. Cannbinoids mediate analgesia largely via peripheral type cannabioid receptors in nociceptors. Nat Neurosci 2007; 10 (7): 870-9
46. Jeske NA, Patwardhan AM, Gamper N, et al. Cannabinoid WIN 55.212-2 regulates TRPV1 phosphorialtion in sensory neurons. J Biol Chem 2006; 281 (43): 32879-90
47. Costa B, Trovato AE, Comelli F, et al. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 2007; 556 (1-3): 75-83
48. Besse D, Lombard MC, Besson JM. Time-related decreases in mu and delta opioid receptors in the superficial dorsal horn of the rat spinal cord following a large unilateral dorsal rhizotomy. Brain Res 1992; 578: 115-27
49. Hohmann AG, Herkenham M. Regulation of cannabinoid and mu opioid receptors in rat lumbar spinal cord following neonatal capsaicin treatment Neurosci Lett 1998; 252: 13-16
50. Farquhar-Smith WP, Egertova M, Bradbury EJ, et al. Cannabinoid CB(1) receptor expression in rat spinal cord. Mol Cell Neurosci 2000; 15: 510-21
51. Siegling A, Hofmann HA, Denzer D, et al. Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain. Eur Pharmacol 2001; 415: R5-7
52. Monhemius R, Azami J, Green DL, et al. CB1 receptor medicated analgesia from the nucleus reticularis gigantocellularis pars alpha is activated in an animal model of neuropathic pain. Brain Res 2001; 908: 67-74
53. Zhang J, Hoffert C, Vu HK, et al. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 2003; 17 (12): 2750-4
54. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988; 33 (1): 87-107
55. Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 1990; 43 (2): 205-18
56. Burchiel KJ, Russell LC, Lee RP, et al. Spontaneous activity of primary afferent neurons in diabetic BB/Wistar rats: a possible mechanism of chronic diabetic neuropathic pain. Diabetes 1985; 34 (11): 1210-3
57. Polomano RC, Mannes AJ, Clark US, et al. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 2001; 94 (3): 293-304
58. Tanner KD, Reichling DB, Levine JD. Nociceptor hyper-responsiveness during vincristine-induced painful peripheral neuropathy in the rat. J Neurosci 1998; 18 (16): 6480-91
59. Shinoda K, Hruby VJ, Porreca F. Antihyperalgesic effects of loperamide in a model of rat neuropathic pain are mediated by peripheral delta-opioid receptors. Neurosci Lett 2007; 411 (2): 143-6
60. Choi Y, Yoon YW, Na HS, et al. Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain 1994; 59 (3): 369-76
61. Pascual D, Goicoechea C, Suardiaz M, et al. A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain 2005; 118 (1-2): 23-34
62. Dogrul A, Gul H, Yildiz O, et al. Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. Neurosci Lett 2004; 368: 82-6
63. Wood HC. Treatise on therapeutics. Philadelphia (PA): JB Lippincott and Co., 1886
64. Hare HA, Chrystie W. A system of practical therapeutics. Vol. 3. Philadelphia (PA): Lee Brothers, 1892
65. Corey S. Recent developments in the therapeutic potential of cannabinoids. P R Health Sci J 2005; 24 (1): 19-26
66. Fisher B, Johnston D, Leake P. Marijuana for medicinal purposes: an evidence-based assessment. Workers' Compensation Board of British Columbia [online]. Available from URL: http://www.worksafebc.com/health_care_providers/ Assets/PDF/marijuana_medicinal_purposes.pdf [Accessed 2007 May 21]
67. Martin CW. Efficacy of marijuana in treating chronic non-cancer pain: a short review. Workers' Compensation Board of British Columbia, Evidence Based Practice Group [online]. Available from URL: http://www.worksafebc.com/ health_care_providers/Assets/PDF/marijuana_medicinal_purposes_update.pdf [Accessed 2007 May 21]
68. Campbell FA, Tramer MR, Carroll D, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323 (7303): 13-6
69. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362 (9395): 1517-26
70. Wade DT, Robson P, House H, et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clinical Rehab 2003; 17 (1): 21-9
71. Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65 (6): 812-9
72. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised, double-blind, placebo-controlled, crossover trial. BMJ 2004; 329 (7460): 253-7
73. Wissel J, Haydn T, Müller J, et al. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol 2006; 253 (10): 1337-41
74. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004; 112 (3): 299-36
75. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007; 68 (7): 515-21
76. Karst M, Salim K, Burstein S, et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003; 290 (13): 1757-62
77. Salim K, Schneider U, Burstein S, et al. Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Neuropharmacology 2005; 48 (8): 1164-71
78. Pinsger M, Schimetta W, Volc D, et al. Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain: a randomized controlled trial. Wien Klin Worchenschr 2006; 118 (11-12): 327-35
79. Zajicek JP, Sanders HP, Wright DE, et al. Cannbinoids and multiple sclerosis (CAMS) study: safety and efficacy data for 12 month follow up. J Neurol Neurosurg Psychiatry 2005; 76: 1664-9
80. Petersen KL, Rowbotham MC. A new human experimental pain model: the heat/capsaicin sensitization model [published erratum appears in Neuroreport 2002 Jan 21; 13 (1): inside back cover]. Neuroreport 1999; 10 (7): 1511-6
81. Burstein S. Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials. AAPS J 2005; 7 (1): E143-8
82. Vann RE, Cook CD, Martin BR, et al. Cannabimimetic properties of ajulemic acid. J Pharmacol Exp Ther 2007; 320 (2): 678-86
83. Crippa JA, Zuardi AW, Garrido GE, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 2004; 29 (2): 417-26
84. Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10 (4): 434-41
85. Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58 (9): 1404-7